Robert E. Hawkins

14.3k citations
206 papers · 23.9k · 11 hit papers · h-index 62

Impact in

Papers in

    • CAR-T cell therapy research 48
    • Cancer Immunotherapy and Biomarkers 15
    • Immunotherapy and Immune Responses 44
    • T-cell and B-cell Immunology 11

Robert E. Hawkins

204 papers receiving 23k citations

Robert E. Hawkins's Hit Papers

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma 2019 · 2.7k citations
2.7k0+11+22Years since publication1k2k3k

Peers

Robert E. Hawkins
Comparison fields: 5 of 140
  • Oncology 6.9k
  • Pulmonary and Respiratory Medicine 9.3k
  • Immunology 2.4k
  • Radiology, Nuclear Medicine and Imaging 2.2k
  • Cancer Research 544
Replace Masayuki Noguchi with:
Masayuki Noguchi Japan
James Gulley United States
Kim Allyson Margolin United States
John D. Wagstaff United Kingdom
Anthony Michael Joshua Australia
Laura Q.M. Chow United States
Rosemarie Mick United States
Alfons J.M. van den Eertwegh Netherlands
Richard D. Carvajal United States
Axel Hoos United States
Robert E. Hawkins relative to Masayuki Noguchi Japan Masayuki Noguchi's profile →
Citations per field
00.5×1.5×2.0×
Masayuki Noguchi · 1×
Citations per year

Countries citing papers authored by Robert E. Hawkins

Since Specialization
Citations

This map shows the geographic impact of Robert E. Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Hawkins more than expected).

Fields of papers citing papers by Robert E. Hawkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Hawkins. The network helps show where Robert E. Hawkins may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert E. Hawkins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert E. Hawkins Line = papers co-authored together Robert E. Hawkins links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 206 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Hit paper breakdown →
20183686
2
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Hit paper breakdown →
20192674
3
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Hit paper breakdown →
20102072
4
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Hit paper breakdown →
20131585
5
Making Antibodies by Phage Display Technology
Hit paper breakdown →
19941308
6
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Hit paper breakdown →
2019826
7
Cancer classification using the Immunoscore: a worldwide task force
Hit paper breakdown →
2012694
8
Selection of phage antibodies by binding affinity
Hit paper breakdown →
1992437
9
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Hit paper breakdown →
2013379
10
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Hit paper breakdown →
2016361
11 2017339
12
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Hit paper breakdown →
2014330
13 2005280
14 2005277
15 2010222
16 2002215
17 2010215
18 1996202
19 2007178
20 1993177

About Robert E. Hawkins

Robert E. Hawkins is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 206 papers that have together received 23.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (53 papers), CAR-T cell therapy research (48 papers), Immunotherapy and Immune Responses (44 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Cancer Immunotherapy and Biomarkers (15 papers), Virus-based gene therapy research (12 papers), T-cell and B-cell Immunology (11 papers) and Gastric Cancer Management and Outcomes (5 papers). The work is most often cited by research in Oncology (6.9k citations), Pulmonary and Respiratory Medicine (9.3k citations), Immunology (2.4k citations), Radiology, Nuclear Medicine and Imaging (2.2k citations) and Cancer Research (544 citations). Robert E. Hawkins has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Greg P. Winter, David Edward Gilham, Andrew D. Griffiths, Hennie R. Hoogenboom, Stephen J. Russell, Cezary A. Szczylik, Cora Nanette Sternberg, John D. Wagstaff, Lauren A. McCann and Ian D. Davis. Their work appears in journals such as British Journal of Cancer, Cancer Immunology Immunotherapy, Journal of Immunotherapy, Annals of Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact